Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00035024.xml
Thromb Haemost 1981; 45(01): 086-089
DOI: 10.1055/s-0038-1650135
DOI: 10.1055/s-0038-1650135
Original Article
Influence of ω-Aminoacids on the Activation of the First Component of Complement at Low Ionic Strength
Further Information
Publication History
Received 07 October 1980
Accepted 22 December 1980
Publication Date:
04 July 2018 (online)
Summary
Cl, the first component of human complement, was activated to Cls by diluting human plasma in a solution of low ionic strength. The addition of lysine and its related aminoacids to plasma resulted in inhibition of Cl activation, α, ω-diaminoacids such as lysine and ornithine were most effective and ω-aminoacids such as 6 aminohexanoic acid were far less effective. Tranexamic acid which is most potent in inhibition of fibrinolysis among those aminoacids was least effective in the inhibition of Cl activation, ω-aminoacids or their analogues hardly inhibited Cls which had already been activated.
-
References
- 1 Haines AL, Lepow IH. Studies on human C’l-esterase. I. Purification and enzymatic properties. J Immunol 1964; 92: 456-467
- 2 Nelson RA JR, Jensen J, Gigli I, Tamura N. Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum. Immunochemistry 1966; 03: 111-135
- 3 Sakai K, Stroud RM. Purification, molecular properties, and activation of Cl proesterase, Cls. J Immunol 1973; 110: 1010-1020
- 4 Soter NA, Austen KF, Gigli I. Inhibition by e-amino-caproic acid of the activation of the first component of complement system. J Immunol 1975; 114: 928-932
- 5 Sheffer AL, Austen KF, Rosen FS. Treatment of hereditary angioneurotic edema with trans-AMCHA. J Allergy Clin Immunol 1972; 49: 133
- 6 Sheffer AL, Fearon DT, Austen KF, Rosen FS. Tranexamic acid. Preoperative prophylactic therapy for patients with hereditary angioneurotic edema. J Allergy Clin Immunol 1977; 60: 38-40
- 7 Donaldson VH, Ratnoff OD, Dias da Silva W, Rosen FS. Permeability-increasing activity in hereditary angioneurotic edema plasma. II Mechanism of formation and partial characterization. J Clin Invest 1969; 48: 642-653
- 8 Takada A, Takada Y. Effects of tranexamic acid, t-AMCHA, and its cis-isomer on the complement system in vitro and in vivo: Possible relationship between coagulation and complement systems. Thrombos Res 1978; 13: 193-205
- 9 Takada Y, Arimoto Y, Mineda H, Takada A. Inhibition of the classical and alternative pathways by amino acids and their derivatives. Immunology 1978; 34: 509-515
- 10 Takada A, Ohashi H, Matsuda H, Takada Y. Effects of tranexamic acid, cis-AMCHA, and 6-aminohexanoic acid on the activation rate of plasminogen by urokinase in the presence of clot. Thrombos Res 1979; 14: 915-923
- 11 Takada A, Urano T, Takada Y. Influence of coagulation on the activation of plasminogen by streptokinase and urokinase. Thromb Haemostas 1979; 42: 901-908
- 12 Trumpi-Kalshoven MM. The relevance of Cl inhibitor in the inhibition of the fibrinolytic activity of plasmin. In: Progress in chemical fibrinolysis and thrombolysis. Davidson JF, Rowan MM, Samama MM, Desnoyers PC. (Eds.) Raven; New York: 1978. vol. 03. 257-267
- 13 Takahashi K, Nagasawa A, Koyama J. The NH2-terminal sequences of a subunit of the first component of human complement, Cls, and its activated form Cls. FEBS Lett 1975; 50: 330-333
- 14 Roberts PS. Measurement of the rate of plasmin on synthetic substrates. J Biol Chem 1958; 238: 285-291
- 15 Takada A, Takada Y. Interaction of Cls and Cl inactivator in the presence of heparin, dextran sulfate and protamine sulfate. Thromb Res 1980; 18: 847-859
- 16 Harpel PC, Cooper NR. Studies on human plasma Cl inactivator enzyme interactions. I. Mechanism of interaction with Cls, plasmin, and trypsin. J Clin Invest 1975; 55: 593-604
- 17 Ratnoff OD, Naff GB. The conversion of C'ls to C’l esterase by plasmin and trypsin. J Exp Med 1967; 125: 337-358
- 18 Ward PA. A plasmin-split fragment of C’3 as a new chemotactic factor. J Exp Med 1967; 126: 189-206
- 19 Polley MJ, Nachman RL. Human complement in thrombin-mediated platelet function. Uptake of the C5b-9 complex. J Exp Med 1979; 150: 633-645
- 20 Muhlfelder JW, Niemetz J, Kreuzer D, Beebe D, Ward PA, Rosenfeld SI. C5 chemotactic fragment induces leucocyte production of tissue factor activity. A link between complement and coagulation. J Clin Invest 1979; 63: 147-150
- 21 Ratnoff OD, Lepow IH. Some properties of an esterase derived from preparations of the first component of complement. J Exp Med 1957; 106: 327-343
- 22 Alkjaersig N, Fletscher AP, Sherry S. ε-aminocaproic acid: an inhibitor of plasminogen activation. J Biol Chem 1959; 234: 832-837
- 23 Okamoto S, Oshiba S, Mihara H, Okamoto U. Synthetic inhibitors of fibrinolysis: In vitro and in vivo mode of action. Ann NY; Acad Sci: 1968. 146. 414-429
- 24 Iwamoto M. Plasminogen-plasmin system. IX. Specific binding of tranexamic acid to plasmin. Thrombos Diathes Haemorrh 1975; 33: 573-585
- 25 Thorsen S. Influence of fibrin on the effect of 6-aminohexanoic add on fibrinolysis caused by tissue plasminogen activator or urokinase. In: Progress in chemical fibrinolysis and thrombolysis. Davidson JF, Rowan RM, Samama MM, Desnoyers PC. (Eds.) Raven; New York: 1978. vol. 03. 269-281